



Synjardy[®], Synjardy XR[®] (empagliflozin/metformin) – New Indication

- On December 23, 2016, the [FDA approved](#) Boehringer Ingelheim's [Synjardy \(empagliflozin/metformin\)](#) and [Synjardy XR \(empagliflozin/metformin extended-release\)](#) to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus (T2DM) and established CV disease.
 - Previously, Synjardy and Synjardy XR were only approved as an adjunct to diet and exercise to improve glycemic control in adults with T2DM when treatment with both [Jardiance[®] \(empagliflozin\)](#) and [metformin](#) is appropriate.
 - The effectiveness of Synjardy and Synjardy XR on reducing the risk of cardiovascular death in adults with T2DM and CV disease has not been established.
 - Synjardy and Synjardy XR are not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
- The newly approved indication for Synjardy and Synjardy XR was based on the [EMPA-REG OUTCOME[®]](#) postmarketing study required by the FDA. The study involved more than 7,000 patients with T2DM and CV disease. In the trial, Jardiance demonstrated significant reductions in CV risk and CV death.
 - When added to standard of care, Jardiance significantly reduced the risk of the combined endpoint (CV death, non-fatal myocardial infarction [MI], or non-fatal stroke) by 14% vs. placebo.
 - In addition, there was a 38% risk reduction in CV death and a 32% risk reduction in all-cause mortality vs. placebo.
- Like other metformin-containing products, Synjardy and Synjardy XR carry a boxed warning for lactic acidosis.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News[®] is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.